Literature DB >> 12418478

Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma? Against.

Christoph von Schilling1.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12418478     DOI： 10.1007/s00259-002-0929-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  18 in total

1.  [High-dose chemotherapy with stem cell transplantation].

Authors:  H Ostermann; W Hiddemann
Journal:  Dtsch Med Wochenschr       Date:  1999-11-19       Impact factor: 0.628

2.  The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL).

Authors:  H C Schouten; S Kvaloy; M Sydes; W Qian; P M Fayers
Journal:  Ann Oncol       Date:  2000       Impact factor: 32.976

3.  Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.

Authors:  P L Weiden; H B Breitz; O Press; J W Appelbaum; J K Bryan; S Gaffigan; D Stone; D Axworthy; D Fisher; J Reno
Journal:  Cancer Biother Radiopharm       Date:  2000-02       Impact factor: 3.099

4.  Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.

Authors:  T E Witzig; C A White; G A Wiseman; L I Gordon; C Emmanouilides; A Raubitschek; N Janakiraman; J Gutheil; R J Schilder; S Spies; D H Silverman; E Parker; A J Grillo-López
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

5.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Authors:  T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

6.  A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.

Authors:  O W Press; J F Eary; T Gooley; A K Gopal; S Liu; J G Rajendran; D G Maloney; S Petersdorf; S A Bush; L D Durack; P J Martin; D R Fisher; B Wood; J W Borrow; B Porter; J P Smith; D C Matthews; F R Appelbaum; I D Bernstein
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

7.  Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.

Authors:  M Magni; M Di Nicola; L Devizzi; P Matteucci; F Lombardi; L Gandola; F Ravagnani; R Giardini; G Dastoli; C Tarella; A Pileri; G Bonadonna; A M Gianni
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

8.  The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.

Authors:  P Dreger; S Martin; R Kuse; R Sonnen; B Glass; N Kröger; R Parwaresch; M Kneba; N Schmitz; R Haas
Journal:  Hematol J       Date:  2000

9.  High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.

Authors:  Ajay K Gopal; Joseph G Rajendran; Stephen H Petersdorf; David G Maloney; Janet F Eary; Brent L Wood; Theodore A Gooley; Sharon A Bush; Lawrence D Durack; Paul J Martin; Dana C Matthews; Frederick R Appelbaum; Irwin D Bernstein; Oliver W Press
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

10.  Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

Authors:  O W Press; J F Eary; F R Appelbaum; P J Martin; W B Nelp; S Glenn; D R Fisher; B Porter; D C Matthews; T Gooley
Journal:  Lancet       Date:  1995-08-05       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.